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Abstract Cells, scaffold, and growth factors are crucially
important in regenerative medicine and tissue engineering.
Progress in science and technology has enabled develop-
ment of these three factors, with basic research being
applied clinically. In the past decade, we have investigated
tissue regeneration in animal models of musculoskeletal
disorders by using cells, scaffold, and delivery systems
which has been relatively easy to apply and develop in
clinical settings. Moreover, microRNA (miRNA), which
are important in biological processes and in the patho-
genesis of human diseases, have been used in research on
regenerative medicine. For the cell source, we focused on
mesenchymal stem cells (MSC) and CD34? and CD133?
cells as endothelial progenitor cells for regeneration of
musculoskeletal organs. These cells are accessible and
safe. For less invasive and more effective therapy, we
developed a novel cell-delivery system using magnetic
force to accumulate cells at a desired site. Furthermore,
administration of synthetic miRNA could enhance tissue
regeneration. In our studies, use of these cells combined
with a cell-delivery system, miRNA, scaffold, and cyto-
kines has led to effective regeneration of musculoskeletal
tissues including cartilage, bone, ligaments, muscle,
peripheral nerves, and spinal cord. The current and future
objective is more effective and less invasive cell-based
therapy with spatial control of transplanted cells by use of
an external magnetic force. Analysis of efficiency, safety,
and the mechanism of tissue regeneration by cells, scaffold,
and miRNA will lead to more promising regenerative
medicine, involving the development of a new generation
of therapy. This review will focus on our regenerative
medicine research, which focuses on clinical application of
cells, scaffold, and miRNA.
Introduction
In 2000, the WHO endorsed the ‘‘Bone and Joint Decade’’
to campaign for promotion of muscloskeletal health.
Muscloskeletal disorders reduce the working population
and, hence, increase the number of elderly people who
prematurely need nursing care [1]. This is an acute problem
in Japan, an example of a so-called ‘‘super-aging society’’.
Muscloskeletal organs consist of four components: bone,
joints, muscles, and nerves. Development of cell biology
and technology has enabled regeneration of these
components.
Cells, scaffold, and growth factors are crucially impor-
tant in regenerative medicine and tissue engineering. Pro-
gress in science and technology has enabled development
of these three factors, with basic research being applied
clinically; this, in turn, has improved the level of health-
care. It is important to choose appropriate cells, scaffold,
and growth factors in tissue regeneration for clinical use.
For the cell source, Yamanaka et al. discovered induced
pluripotent stem cells (iPSC) which can differentiate into
any type of cell as a result of the action of four repro-
gramming factors: c-Myc, Klf4, Oct3/4, and Sox2 [2].
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iPSC will enable regenerative medicine to bring about
radical innovative treatments for musculoskeletal disorders
[3]. However, clinical application of iPSC requires more
time. We have investigated tissue regeneration in muscu-
loskeletal disorders by using autologous cells, scaffold, and
a delivery system which have been used in clinical
applications.
Cells
For the cell source, we focused on mesenchymal stem cell
(MSC) and endothelial progenitor cell (EPC). MSC are an
attractive cell source for regenerative medicine because of
their ability to differentiate into osteogenic, adipogenic,
and chondrogenic lineages [4]. MSC are obtained from
bone marrow and separated from bone marrow aspirate on
the basis of their capacity to adhere to substrates and to
form colony units. MSC are characterized on the basis of
surface expression markers: CD73, CD90, and CD105
positive, and CD34 and CD45 negative [5]. MSC have the
capacity to migrate to an injured site by expression of
receptors and adhesion molecules, and to proliferate and
differentiate within repair tissue. Furthermore, MSC
secrete juxtacrine or paracrine factors that enhance
regeneration from host cells, including stem cells. Several
reports have demonstrated that a cultured medium of MSC
has the potential for tissue regeneration, because it con-
tains exosomes which are complex, 50–200 nm in size,
bi-lipid membrane vesicles [6]. Exosomes contain protein,
mRNA, and miRNA. Further examination of exosomes is
needed to confirm the alternative therapeutic use of MSC
and to investigate the mechanism of tissue regeneration
by MSC transplantation [7]. Until 1997, postnatal new
vessel formation (neovascularization) was believed to be a
function of ‘‘angiogenesis’’, through proliferation and
migration of differentiated endothelial cells, as opposed to
the ‘‘vasculogenesis’’ process through angioblast-induced
neovascularization that was believed to be restricted to
embryonic development [8]. However, circulating EPC
were discovered in adult peripheral blood, demonstrating
the potential for differentiation into endothelial cells
in vitro and neovascularization in vivo. Because of this
character, emerging EPC-based cell therapy has been
applied to ischemic disease, especially in the field of
cardiovascular regeneration. Accumulated basic and clin-
ical data led this strategy into the orthopaedic field, with
the purpose of acceleration of tissue repair via neovascu-
larization. Because the concept of EPC is based on for-
mation of this cell fraction from hemangioblasts, which
are closely linked to hematopoietic stem cells (HSCs),
CD34 and CD133 antigens, commonly used as the surface
markers of HSCs, have been reliable markers and have
been used to obtain EPC on the basis of the first report.
These unique CD34? and CD133? cells have the thera-
peutic potential to:
1. accelerate neovascularization;
2. facilitate tissue repair/regeneration; and
3. modulate the regenerating environment.
Additional advantages of these cell fractions are that
they can be obtained from adult peripheral blood or bone
marrow without culture and then be transplanted to ische-
mic/damaged tissue by use of both systemic and local
injections.
Cell-delivery system
For tissue regeneration it is essential to accumulate cells
effectively at the injured site. Therefore, a cell-delivery
system or method to accumulate cells in the desired area is
required. Our cell-delivery system uses a minimally inva-
sive external magnetic force device (Fig. 1). MSC were
labeled with ferumoxides, dextran-coated superparamag-
netic iron oxide nanoparticles approved by the US Food
and Drug Administration as a magnetic resonance contrast
agent for hepatic imaging of humans. We originally made
an external magnetic device that generated a high magnetic
force, and succeeded in accumulating magnetically labeled
MSC (m-MSC) in the desired area [9]. For cartilage repair,
adhesion of m-MSC to the cartilage defect in this novel
technique was approximately 95 % and higher than in the
local adhesion technique [10].Our study also confirmed
that the proliferation and chondrogenic, osteogenic, and
adipogenic differentiation of m-MSC were not affected by
magnetic labeling and exposure to a magnetic force [10].
To enable clinical use of this cell-delivery technique, we
have worked on regeneration after cartilage, bone, muscle,
and spinal injury in an animal model.
Fig. 1 External magnetic device
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microRNA
In addition to cell therapy, we have examined the potential
of tissue regeneration by microRNA (miRNA) which are
important in biological processes and human diseases.
miRNA are a class of non-coding RNA that regulate gene
expression post-transcriptionally, and are recognized as
one of the major regulators of a variety of biological pro-
cesses, for example the cell cycle, immune function, and
metabolism [11, 12]. miRNA regulate gene expression by
binding 30 UTR of their target mRNA before translational
repression or mRNA degradation. Many miRNA are evo-
lutionarily conserved across phyla, identified from nema-
todes to humans. Because miRNA are of crucial
importance in the pathogenesis of human diseases,
including in the orthopaedic field, miRNA have attracted
attention for developing a novel therapeutic strategy by
targeting miRNA. Because miRNA are essential for the
development and homeostasis of components of musclo-
skeletal organs, for example cartilage, bone, and muscle,
the existence of miRNA in muscloskeletal disorder has
become increasingly important. Interestingly, miRNA cir-
culate in body fluid packaged in microvesicles, for example
exosomes, and are secreted from cells, which have attrac-
ted interest for therapeutic application, for example as
biomarkers [13].
Scaffold
For cell proliferation and differentiation, scaffold provides
a 3-dimensional surrounding environment and growth
factors provide a suitable stimulus. Atelocollagen (Ko-
ken, Tokyo, Japan), type I collagen gel, is a suitable
scaffold and carrier for tissue engineering. It is extracted
from bovine calf skin by pepsin digestion, and immuno-
genicity and a safety problem have been solved by
removing antigenic determinants from the peptide chains
of type I collagen. It has been used clinically since 1986 for
skin disorders and cosmetic surgery; we are, therefore,
focusing on the carrier properties of atolocollagen gel. In a
monolayer culture, chondrocytes assume a dedifferentiated
fibroblastic morphology, with loss of the ability to accu-
mulate a matrix and synthesize predominantly type I col-
lagen. We evaluated the effect of the 3-dimensional culture
of human chondrocytes embedded in atelocollagen gel.
Chondrocytes embedded in atelocollagen gel proliferated
and produced chondroitin 6-sulfate, maintaining the
chondrocyte phenotype for up to 4 weeks [14]. In our
study, atelocollagen was used as the carrier of cells for
articular cartilage, muscle, and nerve repair. Atelocollagen
has been also used as a biomaterial carrier for gene delivery
in vitro and in vivo. Atelocollagen-mediated siRNA or
miRNA delivery is effective for gene silencing in vivo,
because atelocollagen complexed with siRNA or miRNA is
resistant to nuclease and can be efficiently transduced into
cells [15].
Hydroxyapatite ceramic has been used as a bone sub-
stitute because of its good biocompatibility. However,
conventional hydroxyapatite ceramic has poor osteocon-
ductive capacity because of an insufficient number of pore
connections. Interconnected porous calcium hydroxyapa-
tite ceramic (IP-CHA; NEOBONE; MMT, Osaka, Japan)
is an innovative invention because it has spherical uniform
pores, and almost all pores connect through large inter-
connective holes [16]. These features enable the cells and
tissues to penetrate the center of the IP-CHA, providing
good osteoconductivity at an early stage. This feature has
the additional advantage of carrying the cells or growth
factors.
Growth factor/cytokine
To promote cell proliferation or production of an extra-
cellular matrix, application of cytokines or growth factors
is useful. We focused on hyaluronic acid (HA), safe clin-
ical use of which has been confirmed. Under a 3-dimen-
sional culture of chondrocytes, HA has the capacity to
promote cell proliferation and synthesis of chondroitin
sulfate [17]. Application of growth factors or modification
of the environment to up-regulate growth factors or cyto-
kine should be considered for tissue regeneration.
This review will focus on our regenerative medicine
research on cells, scaffold, and miRNA in view of their
clinical application.
Cartilage
In 1994, Brittberg et al. reported successful autologous
chondrocyte implantation (ACI) involving the suspension
of autologous chondrocytes expanded in a monolayer cul-
ture system transplanted into a cartilage defect and covered
with a periosteal flap [18]. Although this report had a big
impact on cartilage repair, there were several lingering
concerns, for example transplantation of dedifferentiated
chondrocytes in a monolayer culture, the risk of leakage of
the transplanted chondrocytes from the cartilage defects,
and uneven distribution of chondrocytes in the transplanted
site by gravity. To solve these problems, we used a
3-dimensional culture system with atelocollagen gel [19].
Our procedure involving tissue engineered cartilage made
ex vivo then transplanted into the cartilage defect and
covered with a periosteal flap has been furnishing good
clinical results since 1996. However, because this trans-
plantation procedure requires an arthrotomy we developed
a tissue-engineered chondral plug [20]. Tissue engineered
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cartilage was placed on type I collagen sponge surrounded
by PLLA mesh, and this chondral plug was successfully
transplanted into the osteochondral defect of the rabbit
patellar groove, producing good results. As a less invasive
MSC procedure, we examined the effect of intra-articular
MSC injection. The effect of the combination therapy of
drilling with intra-articular injection of bone marrow MSC
on the repair of a cartilage defect in a rat model was
examined [21]. The results revealed that the combination
of drilling with an MSC injection is better than drilling
only, suggesting the efficiency of intra-articular injection of
MSC. However, an intra-articular injection containing too
many MSC is problematic. We demonstrated that 1 9 107
MSC generated free bodies of scar tissue in the joint after
an intra-articular injection [22]. Because generation of scar
tissues leads to arthrofibrosis, the optimum number of cells
for tissue regeneration should be defined. To avoid this
problem, a magnetic targeting system for cartilage defects
has been investigated in our laboratory. To examine whe-
ther magnetically labeled cells could accumulate in the
cartilage defect and enable in-vivo repair, the effect of
intra-articular injection of MSC into a large animal with an
external magnetic force was evaluated [10]. A full thick-
ness cartilage defect was created in the center of the patella
in mini-pigs. Four weeks after creation of the cartilage
defect, magnetically labeled MSC (5 9 106 cells) were
injected and were accumulated in the cartilage defect under
a 1.5 T external magnetic force for 10 min (Fig. 2a).
Twelve weeks after injection, arthroscopic findings
revealed good integration in the border zone and the
surface of the regenerated tissue was smooth, with stiffness
nearly normal in the grafts. Twelve and 24 weeks after
injection, histology demonstrated that the cartilage defect
was repaired with hyaline-like cartilage (Fig. 2b). A small
number of magnetically labeled MSC and an external
magnetic force have effective potential for cartilage repair
with hyaline like cartilage, leading to the development of a
novel therapeutic option.
Bone
Although IP-CHA has good osteoconductivity, MSC-loa-
ded IP-CHA would have the potential to accelerate bone
formation for large bone defects. We have demonstrated
excellent bone formation of MSC/IP-CHA composite in the
rat tibial condyle compared with implantation of IP-CHA
only [23]. In this study, implanted MSC survived 8 weeks
after surgery, and differentiated into osteoclast-like cells.
This hybridized IP-CHA is useful for accelerated bone
formation, but a concern remains. In this hybridized tech-
nique, cells are incorporated into the IP-CHA preopera-
tively, but problems such as poor bone formation occur
post-operatively in clinical application. To solve these
problems, a novel cell-delivery system is needed to carry
cells into the center of the graft site. We propose local
injection of magnetically labeled MSC into the bone defect
side in combination with a magnetic targeting system [24].
In our study, IP-CHA was grafted to bridge a rabbit ulnar
defect, and 2 weeks later, magnetically labeled MSC were
Fig. 2 a cartilage defect of mini pig, and intra-articular injection of magnetically labeled MSC into the knee joint under magnetic force.
b Safranin O staining of articular cartilage at 12 weeks
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injected percutaneously into the rabbit ulnar. This external
magnetic targeting system could attract cells into the center
of the IP-CHA, subsequently achieving enhancement of
bone formation even in the chronic phase. However,
because the fate of magnetically labeled MSC was unclear,
we tracked their behavior by use of an in vivo biolumi-
nescence imaging system in the rat non-healing femoral
fracture model; the results demonstrated that the external
magnetic delivery system promoted cell accumulation,
adhesion, and proliferation at the fracture site [25]. These
results suggested the potential clinical use of magnetically
labeled MSC for the treatments of bone defect, delayed
union, and nonunion.
Ligaments
The healing potential of the anterior cruciate ligament (ACL)
is recognized as extremely poor, because rates of cell division
and migration of fibroblasts from the ACL are lower than for
those from the medial collateral ligament [26]. MSC are
useful for ligament healing, because of their high potential for
the proliferation and collagen production. We created an ACL
partially transected model in rats, and injected 1 9 106 MSC
into the knee joint [27]. Four weeks after intra-articular
injection, the transected area was covered with healing tissue,
and the histologic score and ultimate ACL load of the MSC-
injected knee was significantly better than that of the non-
injected knee. These results indicated that injected MSC can
accelerate the healing of a partially torn ACL. Another reason
for poor healing of the ACL is that its blood supply is
restricted, and angiogenesis in the injured ACL occurs very
slowly. MiR-210 is known to be extremely important in
angiogenesis, and is up-regulated in response to hypoxia,
subsequently affecting endothelial cell survival, migration,
and differentiation. Over-expression of miR-210 in endothe-
lial cells can stimulate formation of capillary structure. We
hypothesized that miR-210 administration by intra-articular
injection would accelerate ACL healing via enhancement of
angiogenesis [28]. Expression of miR-210 decreases after
ACL transection but gradually increases after that. An intra-
articular injection of an miR-210 mimic could improve the
biomechanical properties of partially transected ACL,
achieving good coverage of healing tissue with abandoned
vessels on the injured site by up-regulation of VEGF, FGF2,
and collagen type 1, suggesting the possibility of miRNA
therapy for ACL injury.
Muscle
Because such complications as muscle contracture, atro-
phy, and residual pain are often encountered, several
studies have attempted to achieve complete muscle
recovery by use of drugs, cytokines and cell therapy. We
examined muscle regeneration in a rat by transplantation of
bone marrow-derived MSC into a muscle injured site [29].
One month after transplantation, the transplanted MSC had
promoted histological and functional muscle recovery, and
although the mechanism of muscle recovery acceleration
(including cell fate) was not elucidated, these results sug-
gested the usefulness of cell therapy for muscle injury. We
next investigated whether human CD133? cells have the
therapeutic potential for skeletal muscle regeneration in the
rat anterior tibialis muscle laceration model [30]. 1 9 105
CD133? cells were injected locally into an injured muscle
site. It was confirmed that the injected CD133? cells dif-
ferentiate into endothelial and myogenic lineages, and that
they enhance the histological and functional recovery of
injured muscle by inhibiting fibrosis and up-regulating
angiogenesis and myogenesis. Although the transplantation
of human peripheral blood CD133? cells inhibits fibrosis
and improves muscle regeneration in rat skeletal muscle
injury, it is difficult to obtain a sufficient number of cells
because of the small population of CD133? cells. Our
study has confirmed that accumulation of a small number
of cells at an injured site by use of a magnetic cell targeting
system could enhance the regenerative effect of trans-
plantation of CD133? cells [31]. By using a magnetic cell
separation instrument, CD133? cells were labeled with
magnetic beads to isolate them from human peripheral
blood. For magnetic cell targeting, the magnetic field
generator was set up to adjust the peak of magnetic force
gradient at the injured muscle site, following which
1 9 104 CD133? cells were injected locally into the
injured site. The magnetic force enabled the injected
CD133? cells to accumulate in the muscle injury site, with
these cells also inhibiting fibrous scar formation and
enhancing angiogenesis and myogenesis. Muscle injury
was repaired by transplantation of CD133? cells, which
indicated that CD133? cells are a suitable cell source for
muscle repair, and our magnetic cell targeting system could
promote the repair of muscle injury by transplantation of a
limited number of CD133? cells.
MiR-1, miR-133, and miR-206 are well known as potent
regulators of muscle development and homeostasis. Because
these miRNA are down regulated after muscle injury, then
gradually increased thereafter, we investigated whether aug-
mentation of miR-1, miR-133, and miR-203 by local injection
could accelerate muscle regeneration in the rat tibialis anterior
muscle laceration model [32]. One week post-injury, local
injection of these miRNA accelerated muscle regeneration
morphologically and physiologically. Fibrosis was effectively
prevented and blood vessels increased in regenerated muscle.
Local injection of miR-1, miR-133, and miR-206 could
enhance muscle regeneration without use of cell implantation.
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Nerves
In the field of cell therapy, cultured Schwann cells and
neural progenitor cells are candidates for nerve regenera-
tion, but have not yet been applied clinically because of
technical and ethical problems. We hypothesized that it is
feasible to apply CD133? to peripheral nerve regeneration.
A 15-mm defect in the sciatic nerve of athymic rats was
bridged by use of a silicone tube with CD133? cells
embedded in atelocollagen gel [33]. Eight weeks after
transplantation, the defect of the sciatic nerve was struc-
turally regenerated by transplantation of CD133? cells.
The number of myelinated fibers, axon diameter, and
myelin thickness were increased, and compound muscle
action potentials were observed after CD133? cell trans-
plantation. Moreover, transplanted CD133? cells differ-
entiated into Schwann cells. Although transplantation of
CD133? cells could enhance recovery after peripheral
nerve injury, the number of CD133? cells obtained from
peripheral blood is extremely limited. To address this
problem, we transplanted ex-vivo-expanded CD133? cells
into a defect site in the rat sciatic nerve. The fresh CD133?
cells were cultured in serum-free medium supplemented
with 100 ng/ml stem cell factor, 50 ng/ml interleukin-6,
20 ng/ml thrombopoietin, and 100 ng/ml FMS-like tyro-
sine kinase-3 ligand for 7 days [34]. After 1 week of
expansion culture, the number of cells increased 9.6 ± 3.3-
fold; expanded cells comprised 59.0 % CD133? cells and
32.2 % CD133?/CD34? cells, whereas fresh CD133?
cells comprised 93.2 % CD133? cells and 91.2 %
CD133?/CD34? cells, on the basis of FACS analysis. The
histological and functional results of an in-vivo study
confirmed that regenerated nerve fibers in the defect were
similar to the freshly transplanted CD133? cells [35]. The
transplantation of expanded CD133? cells had the poten-
tial for nerve regeneration, which suggested that expanded
CD133? cell transplantation could develop into a novel
therapeutic strategy for nerve regeneration.
Spinal cord
As a novel approach for spinal cord regeneration, we
focused on the close interaction between the nervous sys-
tem and blood vessels described as the ‘‘vascular niche’’.
CD133? cells were administered intravenously in the rat
spinal cord injury (SCI) model [36]. Transplantation of
CD133? cells could enhance intrinsic angiogenesis and
axonal regeneration with significant functional recovery. In
the mechanism of spinal cord regeneration, we proved that
Jag1-Notch signaling from EPC contributes to promoting
repair of the injured spinal cord by enhancement of
astrogliosis [37]. With the purpose of increasing the limited
number of CD133? cells, ex-vivo-expanded CD133? cells
were transplanted intravenously into SCI mice [38].
Transplantation of fresh CD133? and expanded cells
similarly promoted improvement of spinal cord function
after injury compared with administration of PBS or
CD133- mononuclear cell (MNC). To establish a safe and
secure cell transplantation method for SCI, a magnetic cell-
delivery system was used. CD133? cells were transplanted
by the intrathecal route by use of a lumbar puncture in
thoracic spinal cord injury models of immunodeficient rats,
both in the presence of an external magnetic field and in the
absence of an external magnetic field [39]. In-vivo fluo-
rescence imaging showed that administered CD133? cells
accumulated at the injury site at the thoracic level in the
presence of a magnetic field but that almost all adminis-
tered CD133? cells remained in the punctured area of
lumber level in the absence of a magnetic field. Trans-
plantation of CD133? cells in the presence of a magnetic
field promoted axon growth and functional recovery after
spinal cord injury.
Future perspectives
iPSC will lead to a breakthrough in regenerative medicine,
although several issues for clinical use remain to be solved.
Because MSC and EPC have been already applied clini-
cally, we believe our studies using these cells and materials
will enable further development of clinical use in the near
future. To obtain plenty of CD34? or CD133? cells,
mobilization from bone marrow (in-vivo expansion) with
G-CSF (granulocyte-colony-stimulating factor) and sub-
sequent aphaeresis will be required, because of their low
frequency. Therefore, as a future option, ex-vivo expansion
of CD34? or CD133? cells by use of optimized medium
containing growth factor/cytokine cocktails has been tried,
to establish a less invasive and less costly approach for
EPC-assisted tissue regeneration. This new therapeutic
approach will enable more promising and comprehensive
tissue repair/regeneration in orthopaedics. The immediate
purpose is more effective and less invasive cell therapy,
with spatial control of transplanted cells by use of an
external magnetic force. Although there have been many
reports of the effectiveness of cell therapy in tissue
regeneration, its mechanism is yet to be fully elucidated.
Analysis of miRNA/exosome in cell therapy has the
potential to clarify this mechanism, thus leading to novel
alternative cell therapy for tissue regeneration (Fig. 3).
Several reports have revealed that therapeutic trials by
administration of synthetic miRNA or modified antisense
in vivo have been conducted in many fields, hence, miRNA
therapy in clinical orthopaedics will be introduced in the
near future. It is likely that the combination of miRNA and
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an external magnetic device will be more useful and safe,
so any accompanying challenges should be examined to
discover the most effective and least invasive methods.
The new therapeutic strategy of magnetically labeled MSC
with external magnetic force for cartilage injury was adopted
by the Japan Science and Technology Agency in Japan as the
‘‘Highway Program for Realization of Regenerative Medi-
cine’’, and we are now at the stage of realizing clinical
application of cell therapy combined with a magnetic tar-
geting system for cartilage and bone injury, after government
approval. In conclusion, comprehensive analysis of the effi-
ciency, safety, and mechanism of tissue regeneration for
clinical application will lead to more feasible and promising
regenerative medicine as novel next-generation therapy.
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